The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system

Targeting the Effector Site with IFN-  -Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors

(2014) A. J. Currie et al.   JOURNAL OF IMMUNOLOGY

Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study

(2011) A. Carpentier et al.   NEURO-ONCOLOGY

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia

(2010) S Daayana et al.   BRITISH JOURNAL OF CANCER

Improving the Immunogenicity of Pneumococcal Conjugate Vaccine in HIV‐Infected Adults with a Toll‐Like Receptor 9 Agonist Adjuvant: A Randomized, Controlled Trial

(2010) Ole S. Søgaard et al.   CLINICAL INFECTIOUS DISEASES

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

(2010) Joshua D. Brody et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

(2010) Taro Kawai et al.   NATURE IMMUNOLOGY

Adjuvants for cancer vaccines

(2010) Thomas W. Dubensky et al.   SEMINARS IN IMMUNOLOGY

Pharmacokinetic-Pharmacodynamic Modeling of Alpha Interferon Response Induced by a Toll-Like 7 Receptor Agonist in Mice

(2009) N. Benson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

(2009) Jonathan W. Friedberg et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer

(2009) Kazuhiko Yamada et al.   CANCER SCIENCE

Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial

(2009) G. Senti et al.   CLINICAL AND EXPERIMENTAL ALLERGY

TLR9-dependent systemic interferon-β production by intravenous injection of plasmid DNA/cationic liposome complex in mice

(2009) Hiroyuki Yoshida et al.   JOURNAL OF GENE MEDICINE

Targeted Liposomal Delivery of TLR9 Ligands Activates Spontaneous Antitumor Immunity in an Autochthonous Cancer Model

(2009) J. Hamzah et al.   JOURNAL OF IMMUNOLOGY

Immunostimulatory RNA Oligonucleotides Induce an Effective Antitumoral NK Cell Response through the TLR7

(2009) C. Bourquin et al.   JOURNAL OF IMMUNOLOGY

A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia

(2009) D E Spaner et al.   LEUKEMIA

Paternal DNA packaging in spermatozoa: more than the sum of its parts? DNA, histones, protamines and epigenetics

(2009) David Miller et al.   REPRODUCTION

Topical resiquimod promotes priming of CTL to parenteral antigens

(2009) Brent A. Chang et al.   VACCINE

Ampligen: A potential toll-like 3 receptor adjuvant for immunotherapy of cancer

(2009) B. Jasani et al.   VACCINE

TLR9 as a key receptor for the recognition of DNA☆

(2008) Y KUMAGAI et al.   ADVANCED DRUG DELIVERY REVIEWS

Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma

(2008) D.S. Green et al.   BRITISH JOURNAL OF DERMATOLOGY

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

(2008) R. Dummer et al.   CLINICAL CANCER RESEARCH

Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice

(2008) Juliana Hamzah et al.   JOURNAL OF CLINICAL INVESTIGATION

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Christian Manegold et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients

(2008) Julien Fourcade et al.   JOURNAL OF IMMUNOTHERAPY

Treatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod

(2008) Manon van Seters et al.   NEW ENGLAND JOURNAL OF MEDICINE

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

(2008) A M Krieg   ONCOGENE

TLR7 and TLR8 as targets in cancer therapy

(2008) M P Schön et al.   ONCOGENE

The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy

(2008) E. L. J. M. Smits et al.   ONCOLOGIST

Role of neutrophils in BCG immunotherapy for bladder cancer

(2008) Mark P. Simons et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

A clinical grade poly I:C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro

(2008) H. Navabi et al.   VACCINE